Chronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload
Journal of Clinical Apheresis · 2026-06 · 41 (3)
DOI: 10.1002/jca.70147 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 22.06.2026. Verfasst von Daniel Y Chang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Mass General Brigham, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: alpha-Thalassemia, Erythrocyte Transfusion, Iron Overload. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Alpha thalassemia major is a severe hemoglobinopathy characterized by absent or markedly reduced alpha‐globin production, necessitating lifelong blood transfusions. Chronic simple transfusions can lead to significant iron overload, often requiring iron chelation therapy. However, some patients are unable to tolerate chelation or chelation is insufficient, highlighting the need for alternative strategies for managing iron overload. This study is one of the first to evaluate the feasibility, safety, and efficacy of red blood cell exchange (RBCX) as a therapeutic option for managing iron overload while improving hemoglobin function in an alpha thalassemia major patient with iron overload despite chelation therapy. RBCX therapy was performed approximately every 3 weeks over 1 year, with frequent adjustment of exchange parameters to meet pre‐transfusion target levels of functional hemoglobin. Serum ferritin levels, hemoglobin electrophoresis, and functional hemoglobin levels were tracked with each exchange transfusion. For each RBCX treatment, variant hemoglobins decreased by 3.8‐fold (from 19.9% to 8.9%) and functional hemoglobin levels increased approximately 3.0 g/dL. RBCX was well tolerated and associated with a marked reduction in systemic iron burden, with serum ferritin declining 7.4‐fold (86.4%) over 1 year of therapy, followed by a rise after cessation of RBCX. Cardiac iron remained within normal limits throughout the study period. In contrast, liver iron demonstrated a transient increase shortly after initiation of RBCX, but ultimately declined to levels below baseline after 1 year, even during a period in the absence of iron chelation. These findings suggest that RBCX exerts a meaningful effect on iron homeostasis and raises the possibility of a synergistic benefit when combined with iron chelation. This case highlights that RBCX is a viable therapeutic strategy to treat iron overload in patients with alpha thalassemia major.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Mass General Brigham, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Hematology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Arielle Langer, Hiro Nakahara, Ryan Jajosky, David Justus, Li Chai, Mischa Covington, Jun Liu
Zitieren
APA
Chang, D. Y., Shah, S. B., Langer, A., Davis, D., Stowell, S., Sarhan, S., Geary, K., Christiansen, N., Munkacsy, K., Belizaire, R., Nakahara, H., Jajosky, R., Justus, D., Chai, L., Manis, J., Covington, M., & Liu, J. (2026). Chronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload. Journal of Clinical Apheresis, 41(3). https://doi.org/10.1002/jca.70147
Vancouver
Chang DY, Shah SB, Langer A, Davis D, Stowell S, Sarhan S, et al. Chronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload. Journal of Clinical Apheresis. 2026;41(3). doi:10.1002/jca.70147
BibTeX
@article{Chang2026,
author = {Chang, Daniel Y and Shah, Sanjana B and Langer, Arielle and Davis, Dale and Stowell, Sean and Sarhan, Suhayla and Geary, Kristine and Christiansen, Nelya and Munkacsy, Kendra and Belizaire, Roger and Nakahara, Hiro and Jajosky, Ryan and Justus, David and Chai, Li and Manis, John and Covington, Mischa and Liu, Jun},
title = {Chronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload},
journal = {Journal of Clinical Apheresis},
year = {2026},
volume = {41},
number = {3},
doi = {10.1002/jca.70147}
}
EUVIMED